MMMaksim Mamonkin

Maksim Mamonkin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maksim Mamonkin has a total of 286 co-authors. Here are the top co-authors by number of shared publications:

  • Malcolm K. Brenner

    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, Houston, TX 77030, USA; Graduate Program in Immunology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA; Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA

    15 shared publications
  • Madhuwanti Srinivasan

    Texas Children’s Cancer Center, Texas Children’s Hospital, Baylor College of Medicine, Houston, TX 77030, USA

    10 shared publications
  • Norihiro Watanabe

    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital, Houston, Texas, USA

    7 shared publications
  • Feiyan Mo

    Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital and Houston Methodist Hospital, Houston, Texas; Graduate Program in Translational Biology and Molecular Medicine, Baylor College of Medicine, Houston, Texas

    6 shared publications
  • Malini Mukherjee

    Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA

    6 shared publications
  • Nabil Ahmed

    Division of Hematology and Oncology, Department of Pediatrics, Baylor College of Medicine, Texas Children’s Cancer and Hematology Center, Texas Children’s Hospital, Houston, USA

    6 shared publications

Latest Publications

  • Open Access

    Integrating activation-induced costimulation and cytokine signals enhance TCR-based cell therapies

    by Mansi Narula, Johannes Englisch, Cheryl Ou, Tadahiro Honda, Ismael de la Iglesia-San Sebastian, Azlann Arnett, Feiyan Mo, Maksim Mamonkin, Norihiro Watanabe

    TCR-based cell therapies offer broad targeting of tumor antigens with high sensitivity but often low durability due to insufficient costimulation (signal 2) and cytokine (signal 3) support. To address this, we developed a dual stimulatory receptor (DSR) consisting of the 4-1BBL ectodomain fused to the thrombopoietin receptor (cMPL) endodomain. DSR engages 4-1BB that is transiently upregulated upon TCR stimulation eliciting signal 2 and simultaneously activates cMPL-driven STAT3/5 phosphorylation providing signal 3. DSR increases the expansion of T cells, preserving their effector function and an effector-associated transcriptional profile upon repeated antigen stimulation. DSR arming significantly improves in vivo antitumor activity of T cells redirected to cancer through engineered TCRs or soluble T-cell engagers in diverse xenograft tumor models by enhancing T cell expansion and persistence post-infusion. These results demonstrate broad utility and establish DSR as a modular receptor for the effective and synchronized delivery of signals 2 and 3 to support TCR-based immunotherapies.

  • Open Access

    Engineering CAR-Vδ2 T cells to boost persistence and anti-tumor function

    by Leonard Leong, Mansi Narula, Johannes Englisch, Cheryl Ou, Maksim Mamonkin, Norihiro Watanabe

    Chimeric antigen receptor (CAR)-modified Vδ2 T cells are an attractive therapeutic cell platform for cancer immunotherapy. However, their clinical efficacy is limited by short in vivo persistence due to insufficient cytokine support and high susceptibility to activation-induced cell death (AICD). Through comparison of membrane-bound (mb) cytokines, we identified mbIL-18 to support superior anti-tumor activity of CAR-Vδ2 T cells in vitro and in vivo . To reduce constitutive surface exposure of IL-18 and enable antigen-driven signal 3, we fused MyD88 - the key IL-18R signaling mediator - to an extracellular domain of Fas (Fas88). Antigen stimulation-induced FasL engagement of Fas88 triggered IL-18 signaling while simultaneously protecting Vδ2 T cells from AICD. Fas88-armed human CAR-Vδ2 T cells produced superior yet stimulation-dependent in vivo expansion and functional persistence in xenograft models of hematologic and solid malignancies. Together, these findings highlight the importance of IL-18 signaling and AICD resistance for CAR-Vδ2 T cell activity, enabling a single-transgene modification to limit inflammatory risk and facilitate clinical translation.

  • Open Access

    Enhancing CAR- and TCR-mediated targeting of cancer via an immune synapse-stabilizing receptor

    by Chiou-Tsun Tsai, Jorge Ibanez-Vega, Pan Yin, Robert Teis, Norihiro Watanabe, Tadahiro Honda, Mikhail Valkov, Peter J. Chockley, Lourdes Asenath Jimenez Madrigal, Giedre Krenciute, et al.

    Heterogeneity in antigen expression on cancer cells limits clinical benefit of engineered T-cell therapies and underpins treatment resistance through antigen escape. Here, we present a strategy to improve recognition and lysis of tumors with suboptimal antigen expression through a separate engineered receptor that selectively boosts cytotoxic signaling and immune synapse formation. This synapse-stabilizing receptor (SSR) harbors a modified linker for activation of T cells (LAT) endodomain that amplifies CD3ζ signaling upon binding to a secondary tumor antigen resulting in an augmented Ca2+ flux, activation of MAPK and NF-kB signaling, maturation of immune synapse, and enhanced T-cell degranulation. Removing C-terminal amino acids 178-233 in the LAT endodomain (LAT177) was necessary to minimize SSR-mediated cytotoxicity. In models of acute myeloid leukemia, we show that a CD38targeting SSR boosts cytolysis of antigen-low cancer cells via a C-type lectinlike molecule-1 (CLL1)-specific chimeric antigen receptor (CAR) and a survivinspecific T cell receptor (TCR). Unlike another CAR, SSR does not produce significant cytotoxicity against normal CD38+ tissues. Our study thus shows that SSR arming enhances targeting of antigenically heterogeneous cancers without compromising safety and selectivity of therapeutic T cells.


  • To the nines: IL-9 boosts T cell function

    by Elizabeth Wickman, Maksim Mamonkin

  • Open Access

    International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML

    by Swati Naik, Richard Aplenc, Susanne H.C. Baumeister, Marco Becilli, Anand S. Bhagwat, Challice L. Bonifant, Lihua E. Budde, Christopher D. Chien, Kevin J. Curran, Anthony F. Daniyan, et al.

    Early clinical experience with the use of chimeric antigen receptor (CAR) T-cell therapies for patients with acute myeloid leukemia (AML) has been beset by high rates of toxicities and low rates of response. We convened an international workshop with the goal of bringing investigators in the field of AML-directed CAR T-cell therapy together to facilitate discussion of challenges and to brainstorm potential solutions. Based on discussions at the workshop, it was evident that (1) treating and targeting AML with CAR T cells is associated with unique clinical challenges, and (2) variability in clinical trial design, definitions of toxicities, correlative data collection, and reporting methods hinders the field’s ability to compare study outcomes and to develop best practices. Further, details of fundamental CAR T-cell attributes and key correlates of efficacy and toxicity were not uniformly reported in published studies, limiting understanding of barriers to success. These observations led to a concerted team effort in which experts in basic/translational science and clinical investigation from pediatric and adult centers worked together to streamline key attributes of clinical trial design and reporting. Consensus criteria were discussed and agreed upon, leading to the creation of a white paper. These guidelines aim to bolster the overall quality of AML-directed CAR T-cell research, allow for comparisons across trials, and inform the next phase of development of AML-directed CAR T-cell therapies that we hope will improve patient outcomes.


  • CART-007: a license to kill

    by Swati Naik, Maksim Mamonkin

  • Open Access

    Molecular dynamics at immune synapse lipid rafts influence the cytolytic behavior of CAR T cells

    by Ahmed Z. Gad, Jessica S. Morris, Lea Godret-Miertschin, Melisa J. Montalvo, Sybrina S. Kerr, Harrison Berger, Jessica C. H. Lee, Amr M. Saadeldin, Mohammad H. Abu-Arja, Shuo Xu, et al.

    Chimeric antigen receptor T cells (CART) targeting CD19 through CD28.ζ signaling induce rapid lysis of leukemic blasts, contrasting with persistent tumor control exhibited by 4-1BB.ζ-CART. We reasoned that molecular dynamics at the CART immune synapse (CARIS) could explain differences in their tumor rejection kinetics. We observed that CD28.ζ-CART engaged in brief highly lethal CARIS and mastered serial killing, whereas 4-1BB.ζ-CART formed lengthy CARIS and relied on robust expansion and cooperative killing. We analyzed CARIS membrane lipid rafts (mLRs) and found that, upon tumor engagement, CD28.ζ-CAR molecules rapidly but transiently translocated into mLRs, mobilizing the microtubular organizing center and lytic granules to the CARIS. This enabled fast CART recovery and sensitivity to low target site density. In contrast, gradual accumulation of 4-1BB.ζ-CAR and LFA-1 molecules at mLRs built mechanically tonic CARIS mediating chronic Fas ligand–based killing. The differences in CD28.ζ- and 4-1BB.ζ-CARIS dynamics explain the distinct cytolytic behavior of CART and can guide engineering of more adaptive effective cellular products.


  • Open Access

    Chimeric antigen receptor-induced antigen loss protects CD5.CART cells from fratricide without compromising on-target cytotoxicity

    by Royce Ma, Mae Woods, Phillip Burkhardt, Noah Crooks, Dayenne G. van Leeuwen, Daniil Shmidt, Jacob Couturier, Alexandre Chaumette, Divya Popat, LaQuisa C. Hill, et al.